Ignite Creation Date:
2024-05-06 @ 9:11 AM
Last Modification Date:
2024-10-26 @ 12:11 PM
Study NCT ID:
NCT02924402
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-04-11
First Post:
2016-09-14
Brief Title:
Study to Evaluate Safety and Tolerability of XmAb13676 Plamotamab in Patients With CD20-expressing Hematologic Malignancies
Sponsor:
Xencor Inc
Organization:
Xencor Inc
Study Overview
Official Title:
A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 Plamotamab in Patients With CD20-Expressing Hematologic Malignancies
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety and tolerability of intravenous IV and subcutaneous SC administration of XmAb13676 and to determine the maximally tolerated dose MTD andor recommended dose RD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None